The recent portfolio rebalance increased FDL's risk and volatility, with 55% concentration in its top 10 holdings. Read why I ...

Merck slips following its Q2 results as Gardasil sales slump. However, Keytruda, new launches and a rich pipeline bolster its ...

IO Biotech’s cancer vaccine has “narrowly” failed to beat Merck's blockbuster oncology drug Keytruda in a phase 3 melanoma ...

Novo Nordisk, GSK and others need to replenish their pipelines to replace drugs coming off patent. In the past, buying a promising biotech required paying a 100% premium. But high interest rates and ...

China’s drugmakers are racing to roll out cheaper or more innovative alternatives. Read more at straitstimes.com. Read more ...

IO Biotech (NASDAQ:IOBT) announced on Monday that patients with skin tumors who received its lead cancer vaccine candidate, Cylembio, with Merck’s (NYSE:MRK) anti-PD-1 therapy, Keytruda, lived longer ...

An updated guideline on pharmacotherapy of obesity management in adults includes six new and seven revised recommendations, ...

Pharma firms are pouncing on opportunity as patents on world’s second-bestselling drug, which goes by brand names Ozempic and ...

Investing.com -- IO Biotech (NASDAQ: IOBT) stock rose 6.1% after announcing topline results from its pivotal Phase 3 trial of Cylembio, an investigational cancer vaccine, in combination with Merck ...

The system for compensating people injured by vaccines needs significant reform. But the health secretary could alter it in ...

Women with advanced form womb cancer have been given fresh hope after a new treatment was given the green light for ...

Sustained benefits seen in overall survival, progression-free survival, objective response rate with combo vs sunitinib.